Abstract CT210: A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Research

• Publication date

  2014-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.AM2014-CT210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer

  2016cites this paper
• Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies.

  2016cites this paper
• Clinical Translation of Nanomedicine.

  2015cites this paper
• Emerging chemotherapy agents in lung cancer: nanoparticles therapeutics for non-small cell lung cancer

  2015cites this paper
• Nanotechnology in Healthcare: Applications and Challenges

  2015cites this paper